The Oxford Lymphoid Disorders Study Group (OLDSG) was launched in September 2020, and brings together a network of researchers and clinicians form across the University of Oxford and Oxford University Hospitals Trust.

At present, around 3-4% of people will develop either lymphoma or Chronic Lymphocytic Leukemia (CLL) during their lifetime. Together, lymphoma and CLL represent the commonest blood cancer by some margin.

The purpose of OLDSG is to:

• to increase the visibility of lymphoid disorder research in the university
• to foster collaborations between clinicians and laboratory-based scientists leading to high quality translational projects
• to interact with patients and the public at all levels of project development to deliver research which impacts directly on patient need

Group members work on a range of issues relating to lymphoid disorders, haematology, immunology, molecular diagnostics and late effects research.

The group is led by a Dr Graham Collins and a steering group, who help to translate and direct lymphoid research into patient-focused applications. Steering group members include:

For the latest news and publications from members of the OLDSG, please check out our news section, which is kept up to date with the latest research findings, outcomes and cancer-related events from across Oxford.